Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Gastrointestinal Cancers
•
Medical Oncology
Which adjuvant chemotherapy would you offer to a MSI high pancreatic cancer patient after Whipple?
Answer from: Medical Oncologist at Community Practice
Not yet ready for IO alone. Can add IO to FFX maybe.
Sign in or Register to read more
20162
Related Questions
In a patient with metastatic gastric cancer with high PDL-1 CPS score (10), at what point, if any, would you consider omitting chemotherapy and continuing immunotherapy alone based on CHECKMATE 649 if patient has a favorable or complete response?
In which patients with early stage rectal cancer treated according to the PROSPECT paradigm do you recommend adjuvant chemotherapy?
How would you manage a borderline resectable pancreatic cancer s/p induction chemo + chemo-RT who was unable to go to surgery?
What is your preferred third-line therapy for metastatic colon cancer, RAS-WT, MSS, low TMB with no targetable alterations?
Would you consider Trastuzumab Deruxtecan as a second line option for metastatic HER2+ squamous cell carcinoma of the esophagus after progression on FOLFOX + Nivolumab?
Is there a role of adjuvant or systemic therapy for patients with resected stage I colon cancer with subsequent local recurrence S/P a second resection and now has NED?
Would you offer adjuvant therapy for resected GB cancer > 6 months of surgery time if there are high risk features (pT3N0, positive margins, + PNI) and therapy was delayed due to hepatic abscess post operative?
What are your top takeaways in GI Cancers from ESMO 2024?
How would you approach a case of enteroblastic cholangiocarcinoma?
Which patients with metastatic HER2 negative, PD-L1 <1% esophageal cancer patients, would you utilize paclitaxel/ramucirumab maintenance?